OK, so unblinding now is risky, data may not be a

OK, so unblinding now is risky, data may not be a great as we'd thought and hoped for. But sitting on our butts until December of January is also risky. So Cytodyn needs to discuss and consult and weight one risk against the other. Because the pandemic has picked up momentum globally, and nations are desperate, that favors the side to unblind and seek approvals overseas. And big pharma companies are in trials with treatments and now we know that the FDA not only favors BP, but we know the FDA is wiling to respond to the influence and corruption in our wonderful FDA.